Chemomab Therapeutics Ltd. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Chemomab Therapeutics Ltd. (CMMB) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $411.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2021-05-13
- Chemomab Therapeutics Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-03-31 was $411.00K.
- Chemomab Therapeutics Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2020-12-31 was $109.00K, a 88.18% decline year-over-year.
- Chemomab Therapeutics Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2020-09-30 was $1.01M.
- Chemomab Therapeutics Ltd. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2020-06-30 was -$2.03M.
- Chemomab Therapeutics Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was -$1.13M, a 474.09% decline from fiscal 2019.
- Chemomab Therapeutics Ltd. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2019 was $301.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $411.00K 10-Q · filed 2021-05-13 | $520.00K derived: sum of 2 quarters · filed 2021-05-13 | $1.53M derived: sum of 3 quarters · filed 2021-05-13 | -$497.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $1.12M derived: sum of 2 quarters · filed 2021-03-09 | -$908.00K derived: sum of 3 quarters · filed 2021-03-09 | -$1.13M 10-K · filed 2021-03-09 | |
| 2020-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$1.02M derived: sum of 2 quarters · filed 2020-11-16 | -$1.24M 10-Q · filed 2020-11-16 | -$313.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-06-30 | -$2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$2.25M 10-Q · filed 2020-08-14 | -$1.32M derived: sum of 3 quarters · filed 2021-05-13 | -$1.41M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2020-03-31 | -$218.00K 10-Q · filed 2021-05-13 | -$174.00K 10-Q · filed 2020-05-07 | $704.00K derived: sum of 2 quarters · filed 2021-05-13 | $617.00K derived: sum of 3 quarters · filed 2021-05-13 | $303.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $922.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $835.00K derived: sum of 2 quarters · filed 2021-03-09 | $521.00K derived: sum of 3 quarters · filed 2021-03-09 | $301.00K 10-K · filed 2021-03-09 | |
| 2019-09-30 | -$87.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$401.00K derived: sum of 2 quarters · filed 2020-11-16 | -$621.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | -$314.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$534.00K 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | -$220.00K 10-Q · filed 2020-05-07 |